Show simple item record

dc.contributor.authorPeterson, Benjamin E
dc.contributor.authorBhatt, Deepak L
dc.contributor.authorSteg, Ph Gabriel
dc.contributor.authorMiller, Michael
dc.contributor.authorBrinton, Eliot A
dc.contributor.authorJacobson, Terry A
dc.contributor.authorKetchum, Steven B
dc.contributor.authorJuliano, Rebecca A
dc.contributor.authorJiao, Lixia
dc.contributor.authorDoyle, Ralph T
dc.contributor.authorGranowitz, Craig
dc.contributor.authorGibson, C Michael
dc.contributor.authorPinto, Duane
dc.contributor.authorGiugliano, Robert P
dc.contributor.authorBudoff, Matthew J
dc.contributor.authorTardif, Jean-Claude
dc.contributor.authorVerma, Subodh
dc.contributor.authorBallantyne, Christie M
dc.date.accessioned2021-01-21T15:24:30Z
dc.date.available2021-01-21T15:24:30Z
dc.date.issued2020-11-05
dc.identifier.urihttp://hdl.handle.net/10713/14381
dc.description.abstractA total of 8179 randomly assigned patients were followed for 4.9 years (median). First revascularizations were reduced to 9.2% (22.5/1000 patient-years) with icosapent ethyl versus 13.3% (33.7/1000 patient-years) with placebo (hazard ratio, 0.66 [95% CI, 0.58-0.76]; P<0.0001; number needed to treat for 4.9 years=24); similar reductions were observed in total (first and subsequent) revascularizations (negative binomial rate ratio, 0.64 [95% CI, 0.56-0.74]; P<0.0001), and across elective, urgent, and emergent revascularizations. Icosapent ethyl significantly reduced percutaneous coronary intervention (hazard ratio, 0.68 [95% CI, 0.59-0.79]; P<0.0001) and coronary artery bypass grafting (hazard ratio, 0.61 [95% CI, 0.45-0.81]; P=0.0005).en_US
dc.description.urihttps://doi.org/10.1161/CIRCULATIONAHA.120.050276en_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Healthen_US
dc.relation.ispartofCirculationen_US
dc.subjecteicosapentaenoic aciden_US
dc.subjecticosapent ethylen_US
dc.subjectmyocardial revascularizationen_US
dc.subjectprevention & controlen_US
dc.titleReduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.en_US
dc.typeArticleen_US
dc.identifier.doi10.1161/CIRCULATIONAHA.120.050276
dc.identifier.pmid33148016
dc.source.volume143
dc.source.issue1
dc.source.beginpage33
dc.source.endpage44
dc.source.countryUnited States
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record